Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria

The biologic sustained responses in managing sleep interference with numerically higher responses than omalizumab.

Ligelizumab Improves Sleep and Disease Burden in CSU Patients

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

Overlapping Eosinophilic Diseases Linked to Greater Disease Burden in EoE Patients

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

BTK-Inhibition Considered for Dermatologic Conditions 

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

Phase 3 Trial on Dupilumab for Chronic Spontaneous Urticaria Stopped

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

COVID-19 Linked to Exacerbations in Skin Diseases

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Ligelizumab and Omalizumab Optimal Treatments for Chronic Spontaneous Urticaria 

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab. 

Ligelizumab Superior to Omalizumab for Chronic Spontaneous Urticaria Clearance

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic. 

FDA Allows for Omalizumab Self-Injection Across All Indications

The 5 companies issued letters will have 15 days to submit a compliance plan.

FDA Sends Warning Letters for Illegal CBD Products

The HCPLive chronic idiopathic urticaria page is a comprehensive resource for clinical news and insights on CIU. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Chronic Idiopathic Urticaria